Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

August 31, 2012

Conditions
HyperglycemiaAcute Coronary SyndromesMyocardial Infarction
Interventions
DRUG

Exenatide

0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours

Trial Locations (1)

64111

Mid America Heart Institute Saint Luke's Health System, Kansas City

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

lead

Saint Luke's Health System

OTHER

NCT00736229 - Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients | Biotech Hunter | Biotech Hunter